AGIO
Agios Pharmaceuticals, Inc.
34.00$
+2.7%
vs. previous close
Closing price · As of: Sep 21, 2026
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | -14.6% | +47.4% | -0.8% | +39.7% | +3.8% | -4.2% | +68.6% | -13.8% | -24.3% | +77.5% | -22.0% | |
| – | -6.2% | +66.0% | -20.5% | +37.8% | -0.3% | +4.1% | +67.2% | -21.7% | +0.1% | +15.8% | -2.4% | |
| – | +2,579.1% | +52.6% | -1.0% | +41.9% | -90.0% | +57.5% | +59.4% | -31.4% | -36.7% | -13.6% | +16.9% | |
| – | +9.9% | +52.6% | -1.0% | +41.9% | -29.9% | +1.4% | +78.0% | -23.2% | -0.8% | +15.0% | -4.4% | |
| – | -8.4% | -28.3% | -53.8% | +172.0% | +46.7% | +65.8% | -82.8% | -49.6% | +27.4% | +46.2% | +157.4% | |
| – | -5,890,500,100.0% | – | – | – | +743.6% | +100.5% | +10.2% | -47.5% | +124.6% | +44.8% | +19.2% | |
| – | +263.6% | +9.1% | -3.6% | -0.5% | +29.4% | +2.6% | -10.4% | -20.5% | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +11.0% | +247.6% | -8.3% | -28.5% | +46.4% | +81.2% | -67.9% | -5.4% | -8.6% | -3.1% | -14.8% | |
| – | -13.4% | +67.2% | +7.4% | -1.5% | -0.7% | +1.6% | -36.6% | +4.7% | +8.5% | +19.4% | +1.3% | |
| – | -67.2% | +3,183.6% | -18.5% | -52.5% | -88.4% | +7.2% | +50.6% | +22.4% | +9.8% | +11.8% | +9.6% | |
| – | +33.3% | +16.0% | +33.1% | -21.5% | +22.5% | -19.1% | -5.8% | +11.5% | -47.5% | +70.2% | +10.3% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | -18.7% | +3.9% | +4.7% | +83.1% | -6.8% | -37.6% | +223.4% | -14.8% | -26.3% | +90.0% | -22.6% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +11.2% | +4.5% | +19.1% | +23.2% | +4.5% | +15.0% | -12.4% | -9.4% | +1.6% | +4.0% | +0.1% |
Data as of: September 21, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.